News
The U.S. FDA ban on compounded versions of Novo Nordisk's Wegovy has increased its prescriptions by 33%. Despite this, ...
A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will need to show more robust growth in the months ahead to bolster market ...
BlackRock Health Sciences Trust offers a resilient 8.63% dividend yield, low expense ratio, and conservative, low-risk ...
Since the US Food and Drug Administration (FDA) implemented a ban on ‘compounded’ versions of Wegovy on 22 May, new ...
Eli Lilly will soon bring a pill version to the market, with a version expected to debut at a lower price than injectable ...
The market value of the company surpassed the size of Denmark’s entire economy last year and, for a period, Novo Nordisk was ...
Three Motley Fool contributors have picked surprisingly underrated stocks to buy right now. Here's why they chose big pharma ...
13h
The Official Microsoft Blog on MSNHow Microsoft’s customers and partners accelerated AI Transformation in FY25 to innovate with purpose and shape their future successOver the past fiscal year, our customers and partners have driven pragmatic outcomes by implementing AI-first strategies ...
The therapies, which are just starting to enter clinical trials, will need to prove clear clinical and quality-of-life ...
Talking about Morgan Stanley’s bullish call on Eli Lilly and Company (NYSE:LLY), Kevin Simpson, Capital Wealth Planning founder and CIO, said that he agrees with the call and thinks the company’s ...
Eli Lilly's appeal of a decision by the EMA's human medicines committee not to approve its Alzheimer's disease therapy ...
Eli Lilly & Company (NYSE:LLY) ranks among the best low volatility stocks to buy according to analysts. On July 11, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results